Kevin Crowley
Managing Director at Connecticut Innovations
New Haven, Connecticut
Overview
Work Experience
Senior Managing Director, Investments
2006 - Current
Led equity and debt investments in companies like Perosphere, Athletic Brewing, and Budderfly. Leading and managing a ~$40M book for CI's Venture Debt and Mezzanine Debt programs. Oversaw the $46 million Connecticut BioScience Facilities Fund, supporting bioscience companies and creating laboratory space. Coordinated investments for the State's $100MM Stem Cell fund, pioneering one of the first programs in the Country. Led CI's PreSeed program, investing in technology companies at the earliest stage.
Board Member
2023
Perosphere's PoC Coagulometer provides an unprecedented global view of coagulation status where and when it's needed the most, in emergency care. The PoC Coagulometer is the only diagnostic tool that effectively and swiftly monitors clotting processes across drug classes-including DOACs. Adopting the PoC Coagulometer as a new standard of care in the ER holds potential for improved efficiency, significant cost savings, and better patient outcomes due to fast diagnosis and related appropriate treatment decisions.
Board Observer
2021
Enko designs safe and sustainable solutions to farmers’ biggest crop threats today, from pest resistance to new diseases. By applying the latest drug discovery and development approaches from pharma to plants, Enko is bringing an innovation model to agriculture and meeting farmers’ evolving needs.
Board Observer
2021
VeraDermics is a dermatology company that creates novel drug delivery mechanisms for a pain-free cure for skin conditions such as warts. It offers a dissolvable microneedle patch solution that administers immunotherapy without any pain, a treatment that stimulates the body’s own immune system to fight off the wart virus.
Board Observer
2019
BioWave is a non-opioid, FDA cleared, patented, Smarter Pain Blocking Technology that is designed to block pain at the source. It goes beyond old-fashioned TENS products. BioWave is used by over 120 professional sports teams NFL, NHL, NBA, and MLB, and over 160 major NCAA college athletic programs. The BioWaveGO product is a new, non-prescription version of the non-opioid, FDA cleared technology that is now for sale direct to consumers that suffer from chronic pain.
Smarter neurotechnology medical devices that provide instant, long lasting pain relief.
Raised $3,100,000.00 from Connecticut Innovations.
Board Observer
2019
Torigen’s experimental autologous cancer vaccine works by generating a vaccine from a patient's (pet's) deactivated tumor cells to stimulate the immune system against specific tumor-associated antigens found on the outside surface of the tumor cells
Torigen Pharmaceuticals focuses on providing cancer care solutions for animals.
Raised $16,110,000.00 from Werth Ventures, SoGal Ventures, Kema Fund, Gaingels, Ironwood Capital, Connecticut Innovations, Emerald Development Managers, Sidecar Angels, Advantage Capital and Propel(X).
Board Of Directors (Observer status as of 2021)
2017
Trebel is the only free music download app with offline listening. Trebel enables music fans to download the best songs in the world for free and play those songs offline. Other companies offer excellent paid services, but there are more than 2.5 billion smartphone users worldwide who don't pay for music. We provide an answer for anyone who wants an offline option for free music on their smartphone.
Board Observer (Previous Board Member)
2017
At Wellinks, we leverage our empathic and innovative spirit as a catalyst for creating a constellation of care around our members. Through virtual-first human-centered care, we empower greater outcomes for those living with chronic respiratory disease.
Wellinks is a wearable health technology company dedicated to improving clinical outcomes.
Raised $42,600,000.00 from Morningside Ventures, Connecticut Innovations, Benslie Investment Group, Stonehenge Capital and HighCape Partners.
Board of Director Observer (Former Board Member)
2016
CaroGen Corporation is an emerging vaccine immunotherapy company employing a virus-like vesicle (VLV) platform technology developed at Yale University School of Medicine and exclusively licensed for the development and commercialization of vaccine immunotherapies worldwide. Our vision is to create different, potentially transformative first-in-class nanoparticle therapeutic vaccine immunotherapies designed to engage the body’s immune system to both recognize and fight off infectious diseases and cancer. The company is leveraging the VLV platform and developing a portfolio of vaccine candidates against the following infections/diseases: •Chronic Hepatitis B Viral Infection (CHB) in collaboration with Yale School of Medicine and Albany Medical College •Clostridium difficile, a bacterial infection, in collaboration with the University of Connecticut Medical School/Health Center •Zika Virus Infection in collaboration with the Center for Excellence for Vaccine Research (CEVR) at the University of Connecticut The hepatitis B program is CaroGen's lead program and has completed initial proof-of-concept testing in animals which was published in August 2015 in the Journal of Virology. Worldwide, approximately 240 million people live with CHB and 600,000 die each year from HBV-associated liver disease and cancer. The HBV program is undergoing optimization for selection of a clinical candidate capable of stimulating the immune system to multiple HBV target antigens.
CaroGen develops vaccine candidates targeting hepatitis B and C, and other viral agents.
Raised $11,350,000.00 from U.S. Department of Defense, National Institutes of Health and National Institutes of Health.
Board of Directors
2016
A $1.5M fund between Connecticut Innovations, Webster Bank, and UConn devoted to funding early stage UConn related companies.